Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coya Therapeutics (COYA) Non Operating Income (2022 - 2025)

Coya Therapeutics (COYA) has disclosed Non Operating Income for 4 consecutive years, with $325435.0 as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 26.74% to $325435.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, down 19.19% year-over-year, with the annual reading at $1.3 million for FY2025, 19.19% down from the prior year.
  • Non Operating Income hit $325435.0 in Q4 2025 for Coya Therapeutics, up from $317066.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $444232.0 in Q4 2024 to a low of -$3017.0 in Q1 2022.
  • Historically, Non Operating Income has averaged $230242.6 across 4 years, with a median of $245869.0 in 2023.
  • Biggest five-year swings in Non Operating Income: skyrocketed 5523.73% in 2023 and later decreased 26.74% in 2025.
  • Year by year, Non Operating Income stood at $16330.0 in 2022, then skyrocketed by 969.64% to $174672.0 in 2023, then surged by 154.32% to $444232.0 in 2024, then decreased by 26.74% to $325435.0 in 2025.
  • Business Quant data shows Non Operating Income for COYA at $325435.0 in Q4 2025, $317066.0 in Q3 2025, and $319541.0 in Q2 2025.